Literature DB >> 18580816

Sham electroconvulsive therapy studies in depressive illness: a review of the literature and consideration of the placebo phenomenon in electroconvulsive therapy practice.

Keith G Rasmussen1.   

Abstract

The gold standard for the establishment of therapeutic efficacy is the randomized placebo-controlled trial. In the case of electroconvulsive therapy (ECT), there is an older literature of a dozen so-called "sham ECT" trials. When cited, these trials are typically referred to as unequivocally demonstrating the superiority of ECT over sham ECT. However, there is an intriguingly high sham ECT response rate in some of the studies, and there is also some information regarding ECT response of depressive subtypes that informs the modern ECT practitioner. In this report, the sham ECT literature is reviewed in detail, and the author discusses possible mechanisms by which sham-treated patients improved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18580816     DOI: 10.1097/YCT.0b013e3181719b23

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  10 in total

Review 1.  Strategies for Treatment-Resistant Depression: Lessons Learned from Animal Models.

Authors:  Gislaine Zilli Réus; Airam Barbosa de Moura; Laura Araújo Borba; Helena Mendes Abelaira; João Quevedo
Journal:  Mol Neuropsychiatry       Date:  2019-05-21

2.  Primum non nocere. The case for a critical approach to global mental health.

Authors:  P Bracken; J Giller; D Summerfield
Journal:  Epidemiol Psychiatr Sci       Date:  2016-08-15       Impact factor: 6.892

3.  Influence of depressed patients' expectations prior to electroconvulsive therapy on its effectiveness and tolerability (Exp-ECT): a prospective study.

Authors:  Lisa Krech; Michael Belz; Matthias Besse; Isabel Methfessel; Dirk Wedekind; David Zilles
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-09-22       Impact factor: 5.270

Review 4.  Placebo eff ects in psychiatry: mediators and moderators.

Authors:  Katja Weimer; Luana Colloca; Paul Enck
Journal:  Lancet Psychiatry       Date:  2015-03       Impact factor: 27.083

5.  Simulated Electroconvulsive Therapy: A Novel Approach to a Control Group in Clinical Trials.

Authors:  Kaitlin R McManus; Maria I Lapid; Brent P Forester; Martina Mueller; Adriana P Hermida; Louis Nykamp; David G Harper; Stephen J Seiner; Sohag Sanghani; Regan Patrick; Melanie T Gentry; Simon Kung; Janette C Leal; Emily K Johnson; Georgios Petrides
Journal:  J ECT       Date:  2022-03-01       Impact factor: 3.692

6.  ECT Has Greater Efficacy Than Fluoxetine in Alleviating the Burden of Illness for Patients with Major Depressive Disorder: A Taiwanese Pooled Analysis.

Authors:  Ching-Hua Lin; Chun-Jen Huang; Cheng-Chung Chen
Journal:  Int J Neuropsychopharmacol       Date:  2018-01-01       Impact factor: 5.176

Review 7.  Chronic pancreatitis: review and update of etiology, risk factors, and management.

Authors:  Angela Pham; Christopher Forsmark
Journal:  F1000Res       Date:  2018-05-17

8.  Propofol for Treatment-Resistant Depression: A Pilot Study.

Authors:  Brian J Mickey; Andrea T White; Anna M Arp; Kolby Leonardi; Marina M Torres; Adam L Larson; David H Odell; Sara A Whittingham; Michael M Beck; Jacob E Jessop; Derek J Sakata; Lowry A Bushnell; Matthew D Pierson; Daniela Solzbacher; E Jeremy Kendrick; Howard R Weeks; Alan R Light; Kathleen C Light; Scott C Tadler
Journal:  Int J Neuropsychopharmacol       Date:  2018-12-01       Impact factor: 5.176

9.  A response to yet another defence of ECT in the absence of robust efficacy and safety evidence.

Authors:  John Read
Journal:  Epidemiol Psychiatr Sci       Date:  2022-02-15       Impact factor: 6.892

10.  Electroconvulsive Treatment: Hypotheses about Mechanisms of Action.

Authors:  Roar Fosse; John Read
Journal:  Front Psychiatry       Date:  2013-08-27       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.